Drugs that contain Rimegepant Sulfate

1. List of Nurtec Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8314117 BIOHAVEN IRELAND CGRP receptor antagonists
Feb, 2031

(7 years from now)

US8759372 BIOHAVEN IRELAND N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
Feb, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders
Mar, 2039

(15 years from now)

Do you want to check out NURTEC ODT patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 27, 2025
New Indication (I) May 27, 2024

NCE-1 date: 2024-02-28

Market Authorisation Date: 27 February, 2020

Treatment: Acute treatment of migraine with or without aura in adults; Preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

NURTEC ODT family patents

18

United States

6

Korea, Republic of

6

Japan

5

European Union

4

Canada

3

Australia

EA

3

EA

3

Israel

3

Croatia

3

Denmark

3

Spain

3

Portugal

3

Poland

3

Slovenia

3

Mexico

3

RS

3

China

3

Brazil

3

Hungary

3

Lithuania

2

Cyprus

2

Singapore

2

Norway

2

Hong Kong

2

Argentina

1

Colombia

1

Netherlands

1

New Zealand

1

Tunisia

1

Peru

1

Chile

1

Philippines

1

San Marino

1

South Africa

1

Taiwan

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in